Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: a nationwide population-based study in Korea.
Fatty liver index
Healthy people programs
Heart failure
Non-alcoholic fatty liver disease
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
28 04 2020
28 04 2020
Historique:
received:
29
10
2019
accepted:
24
03
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
2
12
2020
Statut:
epublish
Résumé
Heart failure (HF) is relatively common cardiovascular disease with high mortality and morbidity. Although it is associated with many cardiovascular risk factors, the association between nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease, and HF has not been evaluated in a large-scale cohort study. Thus, we evaluated the ability of the fatty liver Index (FLI), a surrogate marker of NAFLD, to predict the development of HF in healthy individuals. We analyzed the association between the FLI and new-onset HF with multivariate Cox proportional-hazards models in 308,578 healthy persons without comorbidities who underwent the National Health check-ups in the republic of Korea from 2009 to 2014. A total of 2532 subjects (0.8%) were newly diagnosed with HF during the study period (a median of 5.4 years). We categorized our subjects into quartile groups according to FLI (Q1, 0-4.9; Q2, 5.0-12.5; Q3, 12.6-31.0; and Q4, > 31.0). The cumulative incidence of HF was significantly higher in the highest FLI group than in the lowest FLI group (Q1, 307 [0.4%] and Q4, 890 [1.2%]; P < 0.001). Adjusted hazard ratio (HRs) indicated that the highest FLI group was independently associated with an increased risk for HF (HR between Q4 and Q1, 2.709; 95% confidence interval = 2.380-3.085; P < 0.001). FLI was significantly associated with an increased risk of new-onset HF regardless of their baseline characteristics. Higher FLI was independently associated with increased risk of HF in a healthy Korean population.
Sections du résumé
BACKGROUND
Heart failure (HF) is relatively common cardiovascular disease with high mortality and morbidity. Although it is associated with many cardiovascular risk factors, the association between nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease, and HF has not been evaluated in a large-scale cohort study. Thus, we evaluated the ability of the fatty liver Index (FLI), a surrogate marker of NAFLD, to predict the development of HF in healthy individuals.
METHODS
We analyzed the association between the FLI and new-onset HF with multivariate Cox proportional-hazards models in 308,578 healthy persons without comorbidities who underwent the National Health check-ups in the republic of Korea from 2009 to 2014.
RESULTS
A total of 2532 subjects (0.8%) were newly diagnosed with HF during the study period (a median of 5.4 years). We categorized our subjects into quartile groups according to FLI (Q1, 0-4.9; Q2, 5.0-12.5; Q3, 12.6-31.0; and Q4, > 31.0). The cumulative incidence of HF was significantly higher in the highest FLI group than in the lowest FLI group (Q1, 307 [0.4%] and Q4, 890 [1.2%]; P < 0.001). Adjusted hazard ratio (HRs) indicated that the highest FLI group was independently associated with an increased risk for HF (HR between Q4 and Q1, 2.709; 95% confidence interval = 2.380-3.085; P < 0.001). FLI was significantly associated with an increased risk of new-onset HF regardless of their baseline characteristics.
CONCLUSIONS
Higher FLI was independently associated with increased risk of HF in a healthy Korean population.
Identifiants
pubmed: 32345225
doi: 10.1186/s12872-020-01444-x
pii: 10.1186/s12872-020-01444-x
pmc: PMC7189566
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
204Références
Lancet. 1987 Aug 22;2(8556):435-7
pubmed: 2887735
Clin Sci (Lond). 2007 Aug;113(3):109-18
pubmed: 17600527
Gastroenterology. 2015 Aug;149(2):389-97.e10
pubmed: 25935633
Hepatol Res. 2017 May;47(6):522-532
pubmed: 27379875
Korean Circ J. 2016 Sep;46(5):658-664
pubmed: 27721857
JACC Heart Fail. 2019 Feb;7(2):87-97
pubmed: 30553904
J Hepatol. 2015 May;62(5):1148-55
pubmed: 25477264
Am J Med Sci. 2011 Aug;342(2):120-4
pubmed: 21747279
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
Heart. 2013 Feb;99(3):163-7
pubmed: 23144292
N Engl J Med. 2010 Sep 30;363(14):1341-50
pubmed: 20879883
J Int Med Res. 2018 Sep;46(9):3959-3969
pubmed: 29968484
Lancet. 1999 May 29;353(9167):1838-42
pubmed: 10359409
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Hepatology. 2015 May;61(5):1547-54
pubmed: 25125077
Int J Epidemiol. 2017 Apr 1;46(2):e15
pubmed: 26822938
Int J Cardiol. 2018 Aug 15;265:162-168
pubmed: 29739707
PLoS One. 2015 Mar 17;10(3):e0120443
pubmed: 25781622
Hypertension. 2014 Nov;64(5):924-8
pubmed: 25156167
Heart Vessels. 2018 Jul;33(7):733-739
pubmed: 29288403
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
J Hepatol. 2016 Sep;65(3):589-600
pubmed: 27212244
Hypertension. 2004 Jun;43(6):1324-31
pubmed: 15123571
Nutrition. 2013 Feb;29(2):370-8
pubmed: 23022119
N Engl J Med. 2002 Apr 18;346(16):1221-31
pubmed: 11961152
PLoS One. 2013 Sep 03;8(9):e72928
pubmed: 24019886
Metabolism. 2015 Aug;64(8):879-87
pubmed: 25957758
Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):830-5
pubmed: 22223732
J Clin Invest. 2004 Jul;114(2):147-52
pubmed: 15254578
Int J Cardiol. 2016 Oct 15;221:275-9
pubmed: 27404689
Gastroenterology. 2003 Jul;125(1):117-25
pubmed: 12851877
Eur Heart J. 2013 Sep;34(36):2804-11
pubmed: 23853073
Hepatology. 2015 Sep;62(3):773-83
pubmed: 25914296
Korean Circ J. 2019 Jan;49(1):1-21
pubmed: 30637993
Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):425-439
pubmed: 29713021
Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1855-60
pubmed: 20539015
Kidney Int. 2015 Mar;87(3):497-9
pubmed: 25723632